Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

Overview
Date Founded

2011

Headquarters

620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139

Type of Company

Public

Employees (Worldwide)

56

Industries

Biotechnology

Company Description

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Website
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Chief Scientific Officer

Chief Medical Officer

Chief Legal & Administrative Officer

Chief Business Officer

Vice President-Biology

Vice President, Chemistry & Early Development

Investor

Head-Media Relations

Board of Directors

Executive Chairman at ZappRx, Inc.

Co-Founder at Alnylam Pharmaceuticals, Inc.

Chairman & Chief Executive Officer at Kaleido Biosciences, Inc.

Managing Partner at Polaris Partners

Founder at Samsara Biocapital LLC

President & Chief Executive Officer at Syros Pharmaceuticals, Inc.

Professor at President & Fellows of Harvard College

Former Chief Financial Officer & Senior Vice President at Takeda Oncology Co.

Faculty Member at Whitehead Institute for Biomedical Research

Paths to Syros Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Syros Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time. While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Recent Transactions
Details Hidden

Syros Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Syros Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Syros Pharmaceuticals, Inc. issued Common Stock

Transaction Advisors
Escrow Agent

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Auditor

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Chair, Transactional Department

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Professional

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onSyros Pharmaceuticals, Inc. issued Common Stock

Advisors & Consultants
Advisor

Professional at Blueprint Medicines Corp.

Key Stats and Financials As of 2017
Market Capitalization
$401M
Total Enterprise Value
$175M
Earnings Per Share
$-2.13
Revenue
$1.1M
EBITDAMargin
-4,828.25%
Total Debt
$53K
Total Equity
$65.3M
EBITDA
$-53.2M
Net Profit
$-54M
Debt TEV
0x
TEVNet Income
-3.24x
Enterprise Value Sales
158.96x
Investors
Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time. While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Casdin Capital invests in early stage companies located in the US. The firm targets companies operating in the fields of life sciences and healthcare industry.

Details Hidden

Investor at Seagate Technology LLC

Suppliers
Dana-Farber Cancer Institute, Inc. IT Consulting & Services | Boston, Massachusetts

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Whitehead Institute for Biomedical Research Hospitals & Patient Services | CAMBRIDGE , MA

Whitehead Institute is a world-renowned non-profit research institution dedicated to improving human health through basic biomedical research. By cultivating a deeply collaborative culture and enabling the pursuit of bold, creative inquiry, Whitehead fosters paradigm-shifting scientific achievement. For more than 30 years, Whitehead faculty have delivered breakthroughs that have transformed our understanding of biology and accelerated development of therapies for such diseases as Alzheimer’s, Parkinson’s, diabetes, and certain cancers. Located in Cambridge, Massachusetts, Whitehead Institute was founded in 1982 by businessman and philanthropist Edwin C. “Jack” Whitehead.

RaQualia Pharma, Inc. Pharmaceuticals | Nagoya, AI

RaQualia Pharma, Inc. engages in a research and development based pharmaceutical company that handles discovery, research, development, marketing, and licensing of clinical and preclinical pharmaceutical products and intellectual properties of its technologies. Its medicines focus on pain, gastrointestinal, and auto-immune diseases; inflammation, cancer, and Alzheimer diseases. The company was founded by Atsushi Nagahisa on February 19, 2008 and is headquartered in Nagoya, Japan.

Competitors
Pfizer, Inc. Pharmaceuticals - WASHINGTON, DC

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Celgene Corp. Pharmaceuticals - Summit, New Jersey

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.